期刊文献+

厄贝沙坦通过诱导自噬减轻db/db小鼠肝脏脂肪变 被引量:9

Irbesartan alleviates hepatic steatosis in db/db mice by inducing autophagy
下载PDF
导出
摘要 目的:探讨厄贝沙坦对db/db小鼠脂肪肝的影响及自噬在这一过程中的作用。方法:雄性db/db小鼠24只随机分为模型组和厄贝沙坦组,另选取12只db/m小鼠作为正常对照组。各组分别干预16周后,观察体重、肝指数、血脂、肝功能以及肝脏病理的变化,检测肝组织PI3K/Akt/m TOR信号通路及自噬相关蛋白Atg-7、beclin-1和LC3B的表达情况,并利用电镜观察肝脏自噬小体的变化。结果:与模型组相比,应用厄贝沙坦干预后,db/db小鼠的体重、肝指数、血脂、丙氨酸转氨酶和天冬氨酸转氨酶与模型组相比显著降低(P<0.05),肝脏病理改变明显减轻;肝组织p-PI3K、p-Akt和p-m TOR的表达明显减少,Atg-7、beclin-1和LC3B-Ⅱ的表达明显增加,肝脏自噬小体显著增多(P<0.05)。结论:厄贝沙坦可能通过抑制PI3K/Akt/m TOR信号通路,上调自噬相关蛋白Atg-7、beclin-1和LC3B-Ⅱ表达,进而促进肝细胞自噬,减轻db/db小鼠肝脏脂肪变。 AIM:To investigate the effect of irbesartan on the fatty liver of db/db mice and whether autophagy is involved in the process.METHODS:Male db/db mice(n=24)were randomly divided into model group and irbesartan group,and12db/m mice with similar age and weight were selected as normal control group.After16weeks of intervention respectively,the fatty liver-related parameters including body weight,liver index,blood lipid,liver function and pathological changes in the liver were observed.The protein levels of p-PI3K,p-Akt,and p-mTOR,as well as Atg-7,beclin-1and LC3B in the liver tissues were detected by Western blot,and the autophagosomes in the liver were observed under electron microscope.RESULTS:Compared with the model group,the body weight,liver index,blood lipids,alanine and aspartate aminotransferase were decreased in irbesartan group(P<0.05).Moreover,the pathological changes in the liver were significantly ameliorated in irbesartan group than that of model group.Importantly,the protein levels of p-PI3K,p-Akt and p-mTOR were decreased with irbesartan administration,while the expression of Atg-7,beclin-1and LC3B-Ⅱwas increased(P<0.05),which resulted in a distinct increase in autophagosomes.CONCLUSION:Irbesartan alleviates hepatic steatosis in db/db mice by inhibiting the PI3K/Akt/mTOR signaling pathway and upregulating the protein expression of Atg-7,beclin-1and LC3B-Ⅱ,thereby inducing autophagy in hepatocytes.
作者 钟娟 青姚 吴曙粤 龚望球 龙海波 ZHONG Juan;QING Yao;WU Shu-yue;GONG Wang-qiu;LONG Hai-bo(The First People’s Hospital of Nanning, Nanning 530022, China;Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2018年第3期521-527,共7页 Chinese Journal of Pathophysiology
基金 广西南宁市科技局基金资助项目(No.20163335)
关键词 厄贝沙坦 自噬 PI3K/Akt/mTOR信号通路 脂肪肝 Irbesartan Autophagy PI3K/Akt/mTOR signaling pathway Hepatic steatosis
  • 相关文献

参考文献4

二级参考文献26

  • 1王琛.三七的药效与作用机制[J].中国实用医药,2006,1(5):125-126. 被引量:8
  • 2Farrell G C,Larter C Z.Nonalcoholic fatty liver disease:fromsteatosis to cirrhosis [J].Hepatology,2006,43 (2 Suppl 1):S99-S112.
  • 3de Alwis N M,Day C P.Non-alcoholic fatty liver disease:the mistgradually clears[J].J Hepatol,2008,48 ( Suppl 1):S104-12.
  • 4Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatter liverdisease:a feature of the metabolic syndrome [J].Diabetes,2001,50(8):1844-50.
  • 5Enjoji M,Kotoh K,Kato M,et al.Therapeutic effect of ARBs on in-sulin resistance and liver injury in patients with NAFLD and chro-nic hepatitis C:a pilot study [J].Int J Mol Med,2008,22 (4 ):521-7.
  • 6Haffner S M,Kennedy E,Gonzalez C,et al.A prospective analysisof the HOMA model.The Mexico City Diabetes Study[J].Diabe-tes Care,1996,19(10):1138-41.
  • 7Knodell R G,Ishak K G,Black W C,et al.and appli-cation of a numerical scoring system for assessing histological ac-tivity in asymptomatic chronic active hepatitis [J].Hepatology,1981,1(5):431-5.
  • 8Promrat K,Lutchman G,Uwaifo G I,et al.A pilot study of pioglita-zone treatment for nonalcoholic steatohepatitis [J].Hepatology,2004,39(1):188-96.
  • 9Henriksen J H,Ring-Larsen H.Rosiglitazone:possible complica-tions and treatment of non-alcoholic steatohepatitis ( NASH) [J].J Hepatol,2008,48(1):174-6.
  • 10Marshall T G,Lee B E,Marshall F E.Commoo angiotensin receptorblockers may directly modulate the immune system via VDRPPAR and CCr2b[J] Theor Biol Med Model,2006,3 (1):31-3.

共引文献31

同被引文献75

引证文献9

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部